Are Direct Oral Anticoagulants and Vitamin K Antagonists Comparable for Cerebral Venous Thrombosis?

Data on the safety and efficacy of direct oral anticoagulants (DOACs) to treat cerebral venous thrombosis (CVT) are sparse. Although practice has shifted from vitamin K antagonists (VKAs) to DOACs as first-line therapy for many indications because of lower intracranial bleeding risks and easier monitoring, VKAs are preferred for other indications such as mechanical heart valves or triple-positive antiphospholipid antibody syndrome. The low incidence of CVT overall makes randomized trial data difficult to come by, but large international collaborations can help address these gaps in knowledge and guide clinical practice. Now, researchers report findings from the largest such prospective analysis to date: A cohort study involving 65 hospitals…